Soligenix, Inc. (SNGX)
Oxford Ledge is still expanding full research coverage of SNGX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Soligenix develops treatments for rare diseases and infectious diseases across specialized biotherapeutics and public health solutions segments.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-06-26
- 8-K Delisting / transfer of listing; Departure/election of directors or officers; Other material event; Financial statements and exhibits 2026-06-12
- 8-K Other material event; Financial statements and exhibits 2026-05-28
- 10-Q Quarterly financial report (unaudited) 2026-05-08
- 8-K Other material event; Financial statements and exhibits 2026-04-28
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for SNGX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open SNGX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.